Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer

Li,Peng; Hu,Ting; Wang,Hongsheng; Tang,Ying; Ma,Yue; Wang,Xiaodong; Xu,Yansong; Chen,Guangyu

doi:10.3892/mmr.2019.10471

Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer

Authors:
- Peng Li
- Ting Hu
- Hongsheng Wang
- Ying Tang
- Yue Ma
- Xiaodong Wang
- Yansong Xu
- Guangyu Chen
View Affiliations

Affiliations: Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Beihua University, Jilin 132001, P.R. China, Department of Oncology, The First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130021, P.R. China, Department of Nursing, Affiliated Hospital of Beihua University, Jilin 132001, P.R. China, Medical Department, Huailai County Hospital of Traditional Chinese Medicine, Zhangjiakou, Hebei 075400, P.R. China
Published online on: July 4, 2019 https://doi.org/10.3892/mmr.2019.10471
Pages: 2493-2499

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor kinase substrate 8 (EPS8) plays critical roles in a variety of solid tumors. However, the biologic functions and clinical significance of EPS8‑like 3 (EPS8L3), an EPS8‑related protein, in liver cancer remain unclear. To measure EPS8L3 expression in liver cancer cell lines, reverse transcription‑quantitative PCR and western blot analyses were performed. The correlation between 338 patients with liver cancer and various clinicopathological factors obtained from the Oncomine database were evaluated using the χ2 test. Survival of patients with different expression of EPS8L3 was determined using Kaplan‑Meier survival analysis with a log rank test, and Cox regression analysis was performed to estimate the prognostic significance of EPS8L3 expression. Additionally, cell proliferation and migration were determined using Cell Counting Kit‑8 and wound healing assays. The results revealed that EPS8L3 expression was significantly upregulated in liver cancer tissues and cell lines (P<0.01), and that the expression of EPS8L3 was closely associated with grade (P=0.024) and mortality (P=0.011). Furthermore, survival analysis suggested patients with high EPS8L3 expression exhibited shorter survival compared with those with low EPS8L3 expression. Cox regression analysis indicated that EPS8L3 could be regarded as a prognostic biomarker in patients with liver cancer (hazard ratio, 1.58; 95% confidence interval, 1.085‑2.301; P=0.017). Additionally, in vitro assays revealed that EPS8L3 depletion significantly inhibited liver cancer cell proliferation and migration, and reduced the levels of phosphorylated PI3K and AKT in the PI3K/AKT signaling pathway. Collectively, the results of the present study, for the first time to the best of our knowledge, demonstrated that EPS8L3 serves as an oncogene in liver cancer development; therefore, EPS8L3 may be a valuable prognostic predictor for patients with liver cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Wu M, Liu Z, Zhang A and Li N: Identification of key genes and pathways in hepatocellular carcinoma: A preliminary bioinformatics analysis. Medicine (Baltimore). 98:e142872019. View Article : Google Scholar : PubMed/NCBI
3	Haines K, Sarabia SF, Alvarez KR, Tomlinson G, Vasudevan SA, Heczey AA, Roy A, Finegold MJ, Parsons DW, Plon SE and López-Terrada D: Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. Pediatr Blood Cancer. 66:e277452019. View Article : Google Scholar : PubMed/NCBI
4	Wu M, Liu Z, Li X, Zhang A, Lin D and Li N: Analysis of potential key genes in very early hepatocellular carcinoma. World J Surg Oncol. 17:772019. View Article : Google Scholar : PubMed/NCBI
5	Fu J and Wang H: Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 412:283–288. 2018. View Article : Google Scholar : PubMed/NCBI
6	Della Corte C, Triolo M, Iavarone M and Sangiovanni A: Early diagnosis of liver cancer: An appraisal of international recommendations and future perspectives. Liver Int. 36:166–176. 2016. View Article : Google Scholar : PubMed/NCBI
7	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
8	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yeudall A and Patel V: EPS8 signaling as a therapeutic target in oral cancer. Oral Dis. 24:128–131. 2018. View Article : Google Scholar : PubMed/NCBI
10	Ohshima K, Hatakeyama K, Kanto K, Ide T, Watanabe Y, Moromizato S, Wakabayashi-Nakao K, Sakura N, Yamaguchi K and Mochizuki T: Comparative proteomic analysis identifies exosomal Eps8 protein as a potential metastatic biomarker for pancreatic cancer. Oncol Rep. 41:1019–1034. 2019.PubMed/NCBI
11	Wen Q, Jiao X, Kuang F, Hou B, Zhu Y, Guo W, Sun G, Ba Y, Yu D, Wang D, et al: FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling. EBioMedicine. 40:198–209. 2019. View Article : Google Scholar : PubMed/NCBI
12	Nasri E, Wiesen LB, Knapik JA and Fredenburg KM: Eps8 expression is significantly lower in p16⁺ head and neck squamous cell carcinomas (HNSCCs) compared with p16⁻ HNSCCs. Hum Pathol. 72:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
13	Wang Q and Yong L: Eps8, a therapeutic potential target for cancer. Hum Pathol. 82:300–301. 2018. View Article : Google Scholar : PubMed/NCBI
14	Chen Y, Xie X, Wu A, Wang L, Hu Y, Zhang H and Li Y: A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res. 37:122018. View Article : Google Scholar : PubMed/NCBI
15	Offenhäuser N, Castelletti D, Mapelli L, Soppo BE, Regondi MC, Rossi P, D'Angelo E, Frassoni C, Amadeo A, Tocchetti A, et al: Increased ethanol resistance and consumption in Eps8 knockout mice correlates with altered actin dynamics. Cell. 127:213–226. 2006. View Article : Google Scholar : PubMed/NCBI
16	Tocchetti A, Confalonieri S, Scita G, Di Fiore PP and Betsholtz C: In silico analysis of the EPS8 gene family: Genomic organization, expression profile, and protein structure. Genomics. 81:234–244. 2003. View Article : Google Scholar : PubMed/NCBI
17	Zeng CX, Tang LY, Xie CY, Li FX, Zhao JY, Jiang N, Tong Z, Fu SB, Wen FJ and Feng WS: Overexpression of EPS8L3 promotes cell proliferation by inhibiting the transactivity of FOXO1 in HCC. Neoplasma. 65:701–707. 2018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Chen H, Li H and Chen Q: INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer. Biochem Biophys Res Commun. 477:467–472. 2016. View Article : Google Scholar : PubMed/NCBI
20	Sheng J, Shen L, Sun L, Zhang X, Cui R and Wang L: Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. Cell Prolif. 52:e126092019. View Article : Google Scholar : PubMed/NCBI
21	He YZ, Liang Z, Wu MR, Wen Q, Deng L, Song CY, Wu BY, Tu SF, Huang R and Li YH: Overexpression of EPS8 is associated with poor prognosis in patients with acute lymphoblastic leukemia. Leuk Res. 39:575–581. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li M, Yang J, Zhang L, Tu S, Zhou X, Tan Z, Zhou W, He Y and Li Y: A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res. 38:2112019. View Article : Google Scholar : PubMed/NCBI
23	Chen C, Liang Z, Huang W, Li X, Zhou F, Hu X, Han M, Ding X and Xiang S: Eps8 regulates cellular proliferation and migration of breast cancer. Int J Oncol. 46:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
24	Ding X, Zhou F, Wang F, Yang Z, Zhou C, Zhou J, Zhang B, Yang J, Wang G, Wei Z, et al: Eps8 promotes cellular growth of human malignant gliomas. Oncol Rep. 29:697–703. 2013. View Article : Google Scholar : PubMed/NCBI
25	Schoenherr C, Serrels B, Proby C, Cunningham DL, Findlay JE, Baillie GS, Heath JK and Frame MC: Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells. J Cell Sci. 127:5303–5316. 2014. View Article : Google Scholar : PubMed/NCBI
26	Chen H, Wu X, Pan ZK and Huang S: Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res. 70:9979–9990. 2010. View Article : Google Scholar : PubMed/NCBI
27	Li YH, Xue TY, He YZ and Du JW: Novel oncoprotein EPS8: A new target for anticancer therapy. Future Oncol. 9:1587–1594. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chen YJ, Shen MR, Chen YJ, Maa MC and Leu TH: Eps8 decreases chemosensitivity and affects survival of cervical cancer patients. Mol Cancer Ther. 7:1376–1385. 2008. View Article : Google Scholar : PubMed/NCBI
29	Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH and Choi YH: β-lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol Ther (Seoul). 22:184–192. 2014. View Article : Google Scholar : PubMed/NCBI
30	Fu YL, Zhang QH, Wang XW and He H: Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci. 21:1169–1175. 2017.PubMed/NCBI
31	Paplomata E and O'Regan R: The PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and biomarkers. Ther Adv Med Oncol. 6:154–166. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhang H, Cao Y, Chen Y, Li G and Yu H: Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway. Oncol Lett. 15:5739–5743. 2018.PubMed/NCBI
33	Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T, Wen H, Yang Y, Wang S, Wang J, et al: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 37:522018. View Article : Google Scholar : PubMed/NCBI
34	Xu M, Shorts-Cary L, Knox AJ, Kleinsmidt-Demasters B, Lillehei K and Wierman ME: Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: Role in proliferation and survival. Endocrinology. 150:2064–2071. 2009. View Article : Google Scholar : PubMed/NCBI
35	Wang H, Patel V, Miyazaki H, Gutkind JS and Yeudall WA: Role for EPS8 in squamous carcinogenesis. Carcinogenesis. 30:165–174. 2009. View Article : Google Scholar : PubMed/NCBI